TEC-话题@MedSci

#TEC#

484篇内容 | 2714人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=1652413, encodeId=0623165241300, content=<a href='/topic/show?id=13d01e24509' target=_blank style='color:#2F92EE;'>#TEC#</a>, objectTitle=GSK与Vir Biotechnology达成2.5亿美元交易，合作开发针对新型冠状病毒的化合物和抗体, objectType=article, longId=191695, objectId=5da71916955e, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=5da71916955e, replyNumber=0, likeNumber=0, createdTime=2020-08-30, rootId=0, userName=shock_melon, userId=852f24292001, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=5da71916955e, moduleTitle=GSK与Vir Biotechnology达成2.5亿美元交易，合作开发针对新型冠状病毒的化合物和抗体, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=5da71916955e)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1652435, encodeId=cc5f1652435a1, content=<a href='/topic/show?id=13d01e24509' target=_blank style='color:#2F92EE;'>#TEC#</a>, objectTitle=罗氏Tecentriq联合紫杉醇用于三阴性乳腺癌研究主要终点PFS未能达到, objectType=article, longId=198983, objectId=4d33198983b2, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=4d33198983b2, replyNumber=0, likeNumber=87, createdTime=2020-10-15, rootId=0, userName=shock_melon, userId=852f24292001, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=4d33198983b2, moduleTitle=罗氏Tecentriq联合紫杉醇用于三阴性乳腺癌研究主要终点PFS未能达到, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=4d33198983b2)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1652375, encodeId=8d6616523e58f, content=<a href='/topic/show?id=13d01e24509' target=_blank style='color:#2F92EE;'>#TEC#</a>, objectTitle=DBV Technologies宣布FDA接受Viaskin治疗花生过敏的BLA申报, objectType=article, longId=180548, objectId=ad60180548d0, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=ad60180548d0, replyNumber=0, likeNumber=90, createdTime=2020-08-13, rootId=0, userName=shock_melon, userId=852f24292001, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=ad60180548d0, moduleTitle=DBV Technologies宣布FDA接受Viaskin治疗花生过敏的BLA申报, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=ad60180548d0)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1652417, encodeId=70c3165241e51, content=<a href='/topic/show?id=13d01e24509' target=_blank style='color:#2F92EE;'>#TEC#</a>, objectTitle=ASCO 2020：罗氏的TIGIT单抗tiragolumab与PD-L1单抗Tecentriq联合，延长了非小细胞肺癌患者生存期, objectType=article, longId=194315, objectId=4a69194315ed, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=4a69194315ed, replyNumber=0, likeNumber=107, createdTime=2021-03-21, rootId=0, userName=shock_melon, userId=852f24292001, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=4a69194315ed, moduleTitle=ASCO 2020：罗氏的TIGIT单抗tiragolumab与PD-L1单抗Tecentriq联合，延长了非小细胞肺癌患者生存期, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=4a69194315ed)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1652373, encodeId=715a16523e303, content=<a href='/topic/show?id=13d01e24509' target=_blank style='color:#2F92EE;'>#TEC#</a>, objectTitle=Nat Biotech：媲美CRISPR-Cas9, 新CRISPR 工具探知90%的基因编辑领域, objectType=article, longId=180224, objectId=b4a818022443, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=b4a818022443, replyNumber=0, likeNumber=63, createdTime=2020-09-11, rootId=0, userName=shock_melon, userId=852f24292001, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=b4a818022443, moduleTitle=Nat Biotech：媲美CRISPR-Cas9, 新CRISPR 工具探知90%的基因编辑领域, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=b4a818022443)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1652402, encodeId=c77a165240280, content=<a href='/topic/show?id=13d01e24509' target=_blank style='color:#2F92EE;'>#TEC#</a>, objectTitle=Nat Biotechnol：研究揭示肿瘤治疗新策略, objectType=article, longId=188379, objectId=c4181883e96f, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=c4181883e96f, replyNumber=0, likeNumber=120, createdTime=2020-06-05, rootId=0, userName=shock_melon, userId=852f24292001, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=c4181883e96f, moduleTitle=Nat Biotechnol：研究揭示肿瘤治疗新策略, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=c4181883e96f)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1652414, encodeId=fc951652414ca, content=<a href='/topic/show?id=13d01e24509' target=_blank style='color:#2F92EE;'>#TEC#</a>, objectTitle=FDA授予ADC药物sacituzumab govitecan快速通道指定，用于治疗转移性尿路上皮癌, objectType=article, longId=191734, objectId=89b6191e3439, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=89b6191e3439, replyNumber=0, likeNumber=63, createdTime=2021-02-25, rootId=0, userName=shock_melon, userId=852f24292001, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=89b6191e3439, moduleTitle=FDA授予ADC药物sacituzumab govitecan快速通道指定，用于治疗转移性尿路上皮癌, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=89b6191e3439)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1652389, encodeId=4bda1652389cb, content=<a href='/topic/show?id=13d01e24509' target=_blank style='color:#2F92EE;'>#TEC#</a>, objectTitle=Nat Biotechnol：可穿戴汗液传感器问世, objectType=article, longId=184491, objectId=a9d918449161, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=a9d918449161, replyNumber=0, likeNumber=57, createdTime=2020-03-13, rootId=0, userName=shock_melon, userId=852f24292001, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=a9d918449161, moduleTitle=Nat Biotechnol：可穿戴汗液传感器问世, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=a9d918449161)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1652387, encodeId=b93a165238e3d, content=<a href='/topic/show?id=13d01e24509' target=_blank style='color:#2F92EE;'>#TEC#</a>, objectTitle=罗氏的PD-L1单抗Tecentriq获得FDA批准用于治疗转移性非鳞状非小细胞肺癌, objectType=article, longId=184290, objectId=431b184290f9, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=431b184290f9, replyNumber=0, likeNumber=85, createdTime=2020-06-10, rootId=0, userName=shock_melon, userId=852f24292001, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=431b184290f9, moduleTitle=罗氏的PD-L1单抗Tecentriq获得FDA批准用于治疗转移性非鳞状非小细胞肺癌, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=431b184290f9)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1652403, encodeId=557116524039a, content=<a href='/topic/show?id=13d01e24509' target=_blank style='color:#2F92EE;'>#TEC#</a>, objectTitle=罗氏的PD-L1单抗Tecentriq在美国获得优先审查, objectType=article, longId=188787, objectId=ec53188e8791, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=ec53188e8791, replyNumber=0, likeNumber=62, createdTime=2020-06-29, rootId=0, userName=shock_melon, userId=852f24292001, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=ec53188e8791, moduleTitle=罗氏的PD-L1单抗Tecentriq在美国获得优先审查, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=ec53188e8791)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1652384, encodeId=8ba71652384e5, content=<a href='/topic/show?id=13d01e24509' target=_blank style='color:#2F92EE;'>#TEC#</a>, objectTitle=Biotechnol Bioeng：ZrO2增强的3D打印BCP支架用于骨组织工程, objectType=article, longId=183756, objectId=bc11183e5611, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=bc11183e5611, replyNumber=0, likeNumber=60, createdTime=2020-07-30, rootId=0, userName=shock_melon, userId=852f24292001, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=bc11183e5611, moduleTitle=Biotechnol Bioeng：ZrO2增强的3D打印BCP支架用于骨组织工程, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=bc11183e5611)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1652365, encodeId=13c61652365e8, content=<a href='/topic/show?id=13d01e24509' target=_blank style='color:#2F92EE;'>#TEC#</a>, objectTitle=Nat Biotechnol：解开免疫谜题：iPSC未能在临床上修成正果的原因, objectType=article, longId=178033, objectId=bfbf1e80336e, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=bfbf1e80336e, replyNumber=0, likeNumber=69, createdTime=2020-04-01, rootId=0, userName=shock_melon, userId=852f24292001, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=bfbf1e80336e, moduleTitle=Nat Biotechnol：解开免疫谜题：iPSC未能在临床上修成正果的原因, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=bfbf1e80336e)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1652396, encodeId=9c08165239622, content=<a href='/topic/show?id=13d01e24509' target=_blank style='color:#2F92EE;'>#TEC#</a>, objectTitle=Science：BioNTech针对实体瘤的新型CAR-T疗法在小鼠模型中使肿瘤完全消退, objectType=article, longId=185630, objectId=41c31856306c, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=41c31856306c, replyNumber=0, likeNumber=84, createdTime=2020-12-06, rootId=0, userName=智者为医08, userId=4dfa37, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=41c31856306c, moduleTitle=Science：BioNTech针对实体瘤的新型CAR-T疗法在小鼠模型中使肿瘤完全消退, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=41c31856306c)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1652383, encodeId=02a81652383a8, content=<a href='/topic/show?id=13d01e24509' target=_blank style='color:#2F92EE;'>#TEC#</a>, objectTitle=罗氏的PD-L1单抗Tecentriq联合Avastin在III期肝癌试验中将死亡风险降低了40％以上, objectType=article, longId=183550, objectId=84a4183550aa, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=84a4183550aa, replyNumber=0, likeNumber=68, createdTime=2020-05-01, rootId=0, userName=shock_melon, userId=852f24292001, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=84a4183550aa, moduleTitle=罗氏的PD-L1单抗Tecentriq联合Avastin在III期肝癌试验中将死亡风险降低了40％以上, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=84a4183550aa)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1652379, encodeId=231e16523e93e, content=<a href='/topic/show?id=13d01e24509' target=_blank style='color:#2F92EE;'>#TEC#</a>, objectTitle=罗氏PD-L1单抗Tecentriq联合VEGF单抗Avastin组合治疗肝癌的III期临床成功, objectType=article, longId=181787, objectId=0d52181e8763, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=0d52181e8763, replyNumber=0, likeNumber=58, createdTime=2020-07-12, rootId=0, userName=shock_melon, userId=852f24292001, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=0d52181e8763, moduleTitle=罗氏PD-L1单抗Tecentriq联合VEGF单抗Avastin组合治疗肝癌的III期临床成功, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=0d52181e8763)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1652401, encodeId=0b4616524011b, content=<a href='/topic/show?id=13d01e24509' target=_blank style='color:#2F92EE;'>#TEC#</a>, objectTitle=喜讯！罗氏的Tecentriq在中国获得批准，用于治疗广泛期小细胞肺癌, objectType=article, longId=188190, objectId=a74718819031, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=a74718819031, replyNumber=0, likeNumber=60, createdTime=2020-08-07, rootId=0, userName=shock_melon, userId=852f24292001, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=a74718819031, moduleTitle=喜讯！罗氏的Tecentriq在中国获得批准，用于治疗广泛期小细胞肺癌, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=a74718819031)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1652412, encodeId=ec6d1652412a4, content=<a href='/topic/show?id=13d01e24509' target=_blank style='color:#2F92EE;'>#TEC#</a>, objectTitle=Environmental Science & Technology：纸质分析设备检测社区废水，为COVID-19提供预警, objectType=article, longId=191363, objectId=d30c19136387, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=d30c19136387, replyNumber=0, likeNumber=79, createdTime=2020-10-12, rootId=0, userName=shock_melon, userId=852f24292001, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=d30c19136387, moduleTitle=Environmental Science & Technology：纸质分析设备检测社区废水，为COVID-19提供预警, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=d30c19136387)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1652398, encodeId=f01a16523988a, content=<a href='/topic/show?id=13d01e24509' target=_blank style='color:#2F92EE;'>#TEC#</a>, objectTitle=新上市的BioNTech收购Neon以增强其CAR-T和TCR-T细胞治疗管线, objectType=article, longId=186503, objectId=f6d21865035f, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=f6d21865035f, replyNumber=0, likeNumber=54, createdTime=2020-03-24, rootId=0, userName=shock_melon, userId=852f24292001, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=f6d21865035f, moduleTitle=新上市的BioNTech收购Neon以增强其CAR-T和TCR-T细胞治疗管线, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=f6d21865035f)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1652352, encodeId=222a165235241, content=<a href='/topic/show?id=13d01e24509' target=_blank style='color:#2F92EE;'>#TEC#</a>, objectTitle=Nat biotech：超级CAR-T细胞让肿瘤完全消失！, objectType=article, longId=175135, objectId=e8321e51356f, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=e8321e51356f, replyNumber=0, likeNumber=70, createdTime=2020-06-02, rootId=0, userName=shock_melon, userId=852f24292001, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=e8321e51356f, moduleTitle=Nat biotech：超级CAR-T细胞让肿瘤完全消失！, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=e8321e51356f)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1652420, encodeId=da45165242011, content=<a href='/topic/show?id=13d01e24509' target=_blank style='color:#2F92EE;'>#TEC#</a>, objectTitle=英国NICE批准罗氏的PD-L1单抗Tecentriq，用于治疗三阴性乳腺癌, objectType=article, longId=194614, objectId=d3b0194614fc, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=d3b0194614fc, replyNumber=0, likeNumber=121, createdTime=2021-01-07, rootId=0, userName=shock_melon, userId=852f24292001, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=d3b0194614fc, moduleTitle=英国NICE批准罗氏的PD-L1单抗Tecentriq，用于治疗三阴性乳腺癌, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=d3b0194614fc)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] 梅斯话题小助手

TEC

2020-05-29

shock_melon (审核中...)

前往app查看评论内容

#TEC#

GSK与Vir Biotechnology达成2.5亿美元交易，合作开发针对新型冠状病毒的化合物和抗体

2020-08-30

shock_melon (审核中...)

前往app查看评论内容

#TEC#

罗氏Tecentriq联合紫杉醇用于三阴性乳腺癌研究主要终点PFS未能达到

2020-10-15

shock_melon (审核中...)

前往app查看评论内容

#TEC#

DBV Technologies宣布FDA接受Viaskin治疗花生过敏的BLA申报

2020-08-13

shock_melon (审核中...)

前往app查看评论内容

#TEC#

ASCO 2020：罗氏的TIGIT单抗tiragolumab与PD-L1单抗Tecentriq联合，延长了非小细胞肺癌患者生存期

2021-03-21

shock_melon (审核中...)

前往app查看评论内容

#TEC#

Nat Biotech：媲美CRISPR-Cas9, 新CRISPR 工具探知90%的基因编辑领域

2020-09-11

shock_melon (审核中...)

前往app查看评论内容

#TEC#

Nat Biotechnol：研究揭示肿瘤治疗新策略

2020-06-05

shock_melon (审核中...)

前往app查看评论内容

#TEC#

FDA授予ADC药物sacituzumab govitecan快速通道指定，用于治疗转移性尿路上皮癌

2021-02-25

shock_melon (审核中...)

前往app查看评论内容

#TEC#

Nat Biotechnol：可穿戴汗液传感器问世

2020-03-13

shock_melon (审核中...)

前往app查看评论内容

#TEC#

罗氏的PD-L1单抗Tecentriq获得FDA批准用于治疗转移性非鳞状非小细胞肺癌

2020-06-10

shock_melon (审核中...)

前往app查看评论内容

#TEC#

罗氏的PD-L1单抗Tecentriq在美国获得优先审查

2020-06-29

shock_melon (审核中...)

前往app查看评论内容

#TEC#

Biotechnol Bioeng：ZrO2增强的3D打印BCP支架用于骨组织工程

2020-07-30

shock_melon (审核中...)

前往app查看评论内容

#TEC#

Nat Biotechnol：解开免疫谜题：iPSC未能在临床上修成正果的原因

2020-04-01

智者为医08 (审核中...)

前往app查看评论内容

#TEC#

Science：BioNTech针对实体瘤的新型CAR-T疗法在小鼠模型中使肿瘤完全消退

2020-12-06

shock_melon (审核中...)

前往app查看评论内容

#TEC#

罗氏的PD-L1单抗Tecentriq联合Avastin在III期肝癌试验中将死亡风险降低了40％以上

2020-05-01

shock_melon (审核中...)

前往app查看评论内容

#TEC#

罗氏PD-L1单抗Tecentriq联合VEGF单抗Avastin组合治疗肝癌的III期临床成功

2020-07-12

shock_melon (审核中...)

前往app查看评论内容

#TEC#

喜讯！罗氏的Tecentriq在中国获得批准，用于治疗广泛期小细胞肺癌

2020-08-07

shock_melon (审核中...)

前往app查看评论内容

#TEC#

Environmental Science & Technology：纸质分析设备检测社区废水，为COVID-19提供预警

2020-10-12

shock_melon (审核中...)

前往app查看评论内容

#TEC#

新上市的BioNTech收购Neon以增强其CAR-T和TCR-T细胞治疗管线

2020-03-24

shock_melon (审核中...)

前往app查看评论内容

#TEC#

Nat biotech：超级CAR-T细胞让肿瘤完全消失！

2020-06-02

shock_melon (审核中...)

前往app查看评论内容

#TEC#

英国NICE批准罗氏的PD-L1单抗Tecentriq，用于治疗三阴性乳腺癌

2021-01-07

科室
- - 订阅+
  - 更多科室
工具
服务